Consensus $83.4M. The company states: Revenue from pharma tests and services, enterprise sales, and other customers of approximately $77.2 million for the full year of 2024 compared with $64.1 million for the full year of 2023, an increase of 20%, despite revenue from Natera decreasing 20% to approximately $25.4 million for the full year of 2024.”
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSNL:
- Personalis price target raised to $8 from $7 at BTIG
- Personalis price target raised to $11 from $9 at H.C. Wainwright
- Personalis receives $50M investment from Merck, extends pact with Moderna
- Cathie Wood’s ARK Investment bought 358.6K shares of Personalis today
- Personalis and Tempus AI extend commercial deal to biopharma industry